Boston—Can treatment of hepatitis C infection with new direct-acting antivirals (DAAs) be shortened to...
Following this program, participants should be better able to: Use in a clinical setting important...
In a phase 2a clinical trial, treatment with beclabuvir and a combination of pegylated...
Multidrug Regimen Seen Challenging Recently Approved Drugs from Gilead Sciences U.S. regulators on Friday...
– In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C...
It’s becoming health threat at young age When David Martinez was diagnosed with advanced...
Two studies suggest drugs could yield high cure rates. A new study suggests that...
Can outcomes be sustained with shorter regimens? A new study suggests that some subgroups...
S. Texas Latinos have nation’s highest rate Experts are sounding the alarm on liver...
We got an overview on this important session at The Liver Meeting® 2014 which...